Entrectinib for <scp>ROS1</scp>‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report

Tanimura, Mai; Kataoka, Nobutaka; Kunimatsu, Yusuke; Tsutsumi, Rei; Sato, Izumi; Nakano, Takayuki; Tanimura, Keiko; Takeda, Takayuki

doi:10.1002/rcr2.857

Cited by 5 publications

(3 citation statements)

References 10 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several cases of successful TKI retreatment after crizotinib-induced lung injury have been documented ( 10 , 11 ), there have been cases of lung injury recurrence ( 12 ). However, in a case of entrectinib administration following lung injury induced by crizotinib ( 1 ), entrectinib did not induce lung injury. That study reported that because crizotinib was not discontinued due to disease progression, sequential entrectinib dosing might be helpful in cases where crizotinib-induced lung injury develops.…”

Section: Discussionmentioning

confidence: 93%

“…The first-line treatment of ROS1 -rearranged advanced NSCLC has been successful with the TKIs crizotinib and entrectinib. Although there has been one case in which entrectinib was continued after lung injury caused by crizotinib ( 1 ), there have been no reports of entrectinib-induced lung injury following lung injury caused by crizotinib.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer

et al. 2023

View full text Add to dashboard Cite

We herein report the first case of c-ros oncogene 1 (ROS1)-rearranged advanced non-small-cell lung cancer (NSCLC) in which lung injury was induced by crizotinib and entrectinib. Crizotinib was administered as first-line chemotherapy in a woman in her early 70s with stage IV NSCLC showing ROS1 rearrangement. This resulted in the development of drug-induced organizing pneumonia, which was alleviated by discontinuing drug administration and giving corticosteroids. Following second-line chemotherapy with entrectinib, a similar lung injury was noted. In cases of crizotinib-induced lung injury, physicians must be alert for druginduced lung injury in subsequent treatment with entrectinib.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Due to the rarity of this driver mutation, it is difficult to wait for a prospective study to be conducted to evaluate how effective entrectinib is in a post-crizotinib setting. To our knowledge, the number of case reports written in English concerning entrectinib’s efficacy is limited, especially for ROS1-fusion carcinomas, and this is the fourth case ever reported where entrectinib was administered after crizotinib (Table 1) [11‒21].…”

Section: Discussionmentioning

confidence: 99%

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report

Sawada,

Taniguchi,

Iizuka

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1–2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known to be effective against ROS1-fusion-positive NSCLC, such cases sometimes progress with brain metastases. The most frequently reported crizotinib-resistance mutation is ROS1 G2032R, and some studies have found that even newly developed ROS1 TKIs, such as entrectinib and lorlatinib, show a decreased efficacy against it. The optimal therapies for ROS1-fusion-positive NSCLC and how such cases can be sequenced have not yet been established. Case Presentation: We herein report a patient with ROS1-fusion-positive NSCLC diagnosed at 34 years old. Crizotinib was started at the diagnosis and switched after 25 months to cisplatin/pemetrexed/bevacizumab once the disease progressed with multiple brain metastases that were resistant to stereotactic radiation therapy. The cytotoxic chemotherapy stabilized the patient’s condition for 17 months until he developed leptomeningeal metastasis (LM). He underwent lumboperitoneal shunting and whole-brain radiotherapy, followed by crizotinib re-administration. Despite crizotinib treatment, his neurological symptoms, such as double vision, headache, weakness in the legs, and walking difficulties, progressed. Eventually, subsequent entrectinib treatment was initiated, which resolved all of the symptoms mentioned above. Regrettably, liquid next-generation sequencing had failed to detect the resistance mechanism due to minimal ctDNA in this case. Conclusion: These findings imply that sequential entrectinib administration may be effective in patients with disease progression limited to central nervous system metastases during crizotinib administration.

show abstract

Crizotinib

2021

Reactions Weekly

View full text Add to dashboard Cite

Nausea, vomiting and drug-induced interstitial lung disease: case reportAn 85-year-old woman developed nausea, vomiting and drug-induced interstitial lung disease during treatment with crizotinib for ROS1-rearranged non-small cell lung cancer.The woman referred to the hospital for examination of a mass in the right upper lobe. She had a history of hypertension and dyslipidaemia. Her family history included gastric cancer. Her further evaluations showed ROS1-rearranged non-small cell lung cancer. Thus, she started receiving crizotinib [route not stated] 250mg twice every day that led to partial response. However, she experienced grade 1 nausea and vomiting secondary to crizotinib on day 8 of the crizotinib therapy. Subsequently, the nausea and vomiting worsened to grade 2.Thus, the dose of crizotinib decreased to 250 mg/day and the woman underwent CT scan of the chest on day 115 that showed drug-induced interstitial lung disease caused by crizotinib therapy. Hence, crizotinib was stopped and she was treated with prednisolone. Subsequently, prednisolone was tapered and her interstitial lung disease responded well to prednisolone. Fifteen day after discontinuation of crizotinib, she started receiving entrectinib that led to marginal response. Entrectinib was continued without adverse events [not all durations of treatments to reactions onset and outcomes stated].

show abstract

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report

Cited by 5 publications

References 10 publications

Lung Injury Induced by Crizotinib and Entrectinib in a Patient with <i>ROS1</i>-rearranged Non-small-cell Lung Cancer

Lung Injury Induced by Crizotinib and Entrectinib in a Patient with <i>ROS1</i>-rearranged Non-small-cell Lung Cancer

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report

Crizotinib

Contact Info

Product

Resources

About